Lifecore Biomedical, Inc.
LFCR
$6.41
$0.071.11%
NASDAQ
| 02/23/2025 | 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | |
|---|---|---|---|---|---|
| Net Income | -194.48% | -146.22% | -50.92% | 81.97% | 142.82% |
| Total Depreciation and Amortization | 3.49% | 15.74% | -8.07% | -19.26% | -37.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 214.03% | 145.93% | 37.44% | -67.14% | -168.77% |
| Change in Net Operating Assets | 48.44% | -1,200.76% | 277.74% | -36.84% | -739.46% |
| Cash from Operations | 184.63% | -574.38% | 92.28% | 481.96% | 87.91% |
| Capital Expenditure | 14.31% | 42.03% | 32.88% | 63.24% | 10.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 124.25% | 42.03% | 32.88% | 57.25% | -217.23% |
| Total Debt Issued | -- | 13.47% | -16.09% | -17.75% | 165.51% |
| Total Debt Repaid | -2,585.78% | -5,000.89% | -796.15% | 2.78% | 99.14% |
| Issuance of Common Stock | -- | -- | -99.86% | -- | -- |
| Repurchase of Common Stock | -216.67% | -3,108.33% | -1,208.89% | -- | 82.72% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -108.92% | -- | -- | 95.51% | 232.90% |
| Cash from Financing | -188.80% | 611.23% | -62.75% | -102.50% | 216.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,628.38% | 172.59% | 71.84% | -66.61% | 96.19% |